View in EDS

Cistanche deserticola Polysaccharides Mitigate Alzheimer's Disease Progression by Dynamic Regulation of Gut Microbiota Composition and Metabolites.

Saved in:
Bibliographic Details
Title: Cistanche deserticola Polysaccharides Mitigate Alzheimer's Disease Progression by Dynamic Regulation of Gut Microbiota Composition and Metabolites.
Authors: Gao, Yuan (AUTHOR), Zhang, Chun-Sheng (AUTHOR), Liang, Yan (AUTHOR), Gao, Jie (AUTHOR), Liu, Yang (AUTHOR), Bu, Ren (AUTHOR), Liu, Hong (AUTHOR), Du, Xiao-Li (AUTHOR), Sun, Li-Jun (AUTHOR), Li, Bing (AUTHOR), Li, Gang (AUTHOR)
Source: American Journal of Chinese Medicine. 2025, Vol. 53 Issue 6, p1785-1812. 28p.
Subjects: Chinese medicine, In vitro studies, Flow cytometry, Alzheimer's disease, Herbal medicine, Gut microbiota, Apoptosis, Enzyme-linked immunosorbent assay, In vivo studies, Oxidative stress, Polysaccharides, Metabolites, Mice, RNA, Drug efficacy, Animal experimentation, Western immunoblotting, Metabolomics, Stains & staining (Microscopy), Collection & preservation of biological specimens, Disease progression, Sequence analysis, Therapeutics, Evaluation
Geographic Terms: Mongolia
Abstract: Cistanche deserticola polysaccharides (CDPS) exhibit a range of pharmacological activities, most notably in immune modulation, anti-oxidation, and gut microbiota regulation. Emerging evidence suggests that restoring gut microbial and metabolic homeostasis may decelerate the progression of Alzheimer's disease (AD). However, the specific in vivo effects and underlying mechanisms of CDPS in the context of AD remain incompletely understood. In this study, we employed behavioral tests, 16S rRNA high-throughput sequencing, and time-resolved metabolomic analyses to comprehensively evaluate the therapeutic efficacy of CDPS. CDPS administration significantly ameliorated cognitive impairment, suppressed pro-inflammatory cytokine expression, and reduced A β deposition and Tau hyperphosphorylation in the brains of APP/PS1 Tg mice. These effects were associated with CDPS-induced modulation of gut microbial composition — especially the Firmicutes/Bacteroidetes ratio — and regulation of D-Proline and Histidine metabolism. Further in vitro and in vivo validation confirmed that D-Proline and Histidine, key CDPS-associated metabolites, protected against A β -induced apoptosis and oxidative stress. Notably, the cognitive benefits of CDPS were markedly weakened under conditions of gut microbiota disruption or immune suppression, which highlights the importance of microbial and immune system integrity in mediating its therapeutic effects. Collectively, these findings highlight gut microbial and metabolic disturbances as critical contributors to AD pathogenesis, and support CDPS as a promising multi-target therapeutic strategy. The integration of longitudinal microbiota and metabolomic profiling offers novel mechanistic insights into the neuroprotective actions of CDPS in AD. [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Chinese Medicine is the property of World Scientific Publishing Company and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Cistanche deserticola polysaccharides (CDPS) exhibit a range of pharmacological activities, most notably in immune modulation, anti-oxidation, and gut microbiota regulation. Emerging evidence suggests that restoring gut microbial and metabolic homeostasis may decelerate the progression of Alzheimer's disease (AD). However, the specific in vivo effects and underlying mechanisms of CDPS in the context of AD remain incompletely understood. In this study, we employed behavioral tests, 16S rRNA high-throughput sequencing, and time-resolved metabolomic analyses to comprehensively evaluate the therapeutic efficacy of CDPS. CDPS administration significantly ameliorated cognitive impairment, suppressed pro-inflammatory cytokine expression, and reduced A β deposition and Tau hyperphosphorylation in the brains of APP/PS1 Tg mice. These effects were associated with CDPS-induced modulation of gut microbial composition — especially the Firmicutes/Bacteroidetes ratio — and regulation of D-Proline and Histidine metabolism. Further in vitro and in vivo validation confirmed that D-Proline and Histidine, key CDPS-associated metabolites, protected against A β -induced apoptosis and oxidative stress. Notably, the cognitive benefits of CDPS were markedly weakened under conditions of gut microbiota disruption or immune suppression, which highlights the importance of microbial and immune system integrity in mediating its therapeutic effects. Collectively, these findings highlight gut microbial and metabolic disturbances as critical contributors to AD pathogenesis, and support CDPS as a promising multi-target therapeutic strategy. The integration of longitudinal microbiota and metabolomic profiling offers novel mechanistic insights into the neuroprotective actions of CDPS in AD. [ABSTRACT FROM AUTHOR]
ISSN:0192415X
DOI:10.1142/S0192415X25500661